The Lancet's latest mRNA review reads more like marketing than science

The authors call mRNA vaccines safe, effective & transformative. But the review is largely performative. It raises controversial questions only to defuse them with reassuring conclusions.

The Lancet’s latest review of mRNA vaccines, by Blakney and colleagues, presents itself as an authoritative synthesis of the evidence.

Titled “Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective,” it promises to examine the mRNA platform from mechanistic, preclinical, clinical and public health perspectives.

Instead, it delivers a remarkably confident account that gives little attention to many of the scientific and regulatory questions that have shaped debate over the past five years.

What makes the review effective as messaging is not that it ignores controversy, but that it appears to engage with it.

It names difficult issues — residual DNA, biodistribution, frameshifting and IgG4 class switching — only to swiftly minimise them with reassuring language.

The effect is to create the appearance of critical scrutiny while reassuring readers that these concerns are either resolved or insignificant.